Posted by Michael Wonder on 23 Oct 2024
Lilly's Kisunla (donanemab-azbt) receives marketing authorisation in Great Britain for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease in adult patients who are apolipoprotein E Ε4 heterozygotes or non-carriers
23 October 2024 - Donanemab was first approved in the United States in July 2024 and then approved in Japan in September 2024
Eli Lilly announced today that the MHRA has granted marketing authorisation for donanemab, an injection for intravenous infusion every four weeks to treat mild cognitive impairment and mild dementia due to Alzheimer's disease in eligible adults in Great Britain.
